Literature DB >> 16555057

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.

Deepak P Assudani1, Roger B V Horton, Morgan G Mathieu, Stephanie E B McArdle, Robert C Rees.   

Abstract

Recent years have seen the unprecedented surge of interest in the role of CD4+ T cells and the role they play in the development of the immune response. In this symposium review, we examine the evidence for this and discuss their functions, particularly in respect to the cancer immunology, including CD4+CD25+ cells (Treg).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16555057     DOI： 10.1007/s00262-006-0154-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  10 in total

1.  Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Khaliquzzaman A Samad; Imelda S Quinlin; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Cancer Immunol Immunother       Date:  2011-11-15       Impact factor: 6.968

2.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

3.  T cell survival and function requires the c-Abl tyrosine kinase.

Authors:  Isabelle Silberman; Ronit Vogt Sionov; Valentina Zuckerman; Sue Haupt; Zehavit Goldberg; Andreas Strasser; Zami S Ben-Sasson; Michal Baniyash; Anthony J Koleske; Ygal Haupt
Journal:  Cell Cycle       Date:  2008-12-23       Impact factor: 4.534

4.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

5.  Development and dynamics of robust T-cell responses to CML under imatinib treatment.

Authors:  Christiane I-U Chen; Holden T Maecker; Peter P Lee
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

6.  Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.

Authors:  Reginald M Gorczynski; Zhiqi Chen; Nuray Erin; Ismat Khatri; Anna Podnos
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

7.  Immunomodulatory and anticancer potential of Gan cao (Glycyrrhiza uralensis Fisch.) polysaccharides by CT-26 colon carcinoma cell growth inhibition and cytokine IL-7 upregulation in vitro.

Authors:  Peter Amwoga Ayeka; Yuhong Bian; Peter Githaiga Mwitari; Xiaoqian Chu; Yanjun Zhang; Rosette Uzayisenga; Elick Onyango Otachi
Journal:  BMC Complement Altern Med       Date:  2016-07-11       Impact factor: 3.659

8.  The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.

Authors:  Wei Yao; Jun-Chuang He; Yan Yang; Jian-Ming Wang; Ya-Wei Qian; Tao Yang; Lei Ji
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

9.  Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.

Authors:  Reginald M Gorczynski; Zhiqi Chen; Ismat Khatri; Anna Podnos; Kai Yu
Journal:  Breast Cancer Res Treat       Date:  2013-10-29       Impact factor: 4.872

10.  The immunomodulatory activities of licorice polysaccharides (Glycyrrhiza uralensis Fisch.) in CT 26 tumor-bearing mice.

Authors:  Peter Amwoga Ayeka; YuHong Bian; Peter Mwitari Githaiga; Ying Zhao
Journal:  BMC Complement Altern Med       Date:  2017-12-15       Impact factor: 3.659
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.